Table 6.6a

Immunosuppression Use for Induction, 1994 to 2003

Recipients with Pancreas Transplant Alone (PTA) Transplants

	Year of Transplant
	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
Transplants	40	41	53	79	88	137	135	165	177	159
Tx With Immunosuppression Info	40	41	50	77	80	133	127	157	159	130
No Induction Drugs Recorded	70.0%	41.5%	34.0%	41.6%	41.3%	36.8%	30.7%	38.2%	32.1%	20.8%
Drugs	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ALG
ATG/NRATG/NRATS	0.0%	12.2%	22.0%	18.2%	15.0%	8.3%	0.0%	0.0%	0.0%	1.5%
OKT3	30.0%	46.3%	44.0%	39.0%	22.5%	7.5%	4.7%	3.2%	2.5%	0.0%
Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	30.1%	48.0%	50.3%	58.5%	35.4%
Zenapax	0.0%	0.0%	0.0%	1.3%	31.3%	30.8%	43.3%	35.0%	34.0%	10.0%
Simulect	0.0%	0.0%	0.0%	0.0%	3.8%	11.3%	9.4%	3.2%	4.4%	7.7%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	35.4%

Source: OPTN/SRTR Data as of May 3, 2004.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.